# OnCo record sidewinder-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/sidewinder-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "sidewinder-therapeutics" ;
  schema:name "Sidewinder Therapeutics"@en ;
  schema:description "Sidewinder Therapeutics designs antibody-drug conjugates that bind two proteins found together on some solid tumours, so the cell-killing drug is taken up mainly by cancer cells. It is aiming at squamous lung, head and neck and bowel cancers, with its first human trial expected in 2027."@en ;
  schema:url <https://onco.cc/companies/sidewinder-therapeutics/>, <https://sidewinderbio.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://sidewinderbio.com/>, <https://sidewinderbio.com/news/sidewinder-therapeutics-announces-137-million-series-b-financing-to-advance-precision-bispecific-adcs-into-clinical-development-for-cancer/>, <https://sidewinderbio.com/news/lonzas-synaffix-and-sidewinder-therapeutics-announce-multi-target-license-agreement-to-advance-development-of-next-generation-bispecific-adcs/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-adc/>, <https://onco.cc/technologies/adc/> .